top of page

What We Do
Resources
- Navigating Market Access
Case Studies & Blogs
About Us

Case Studies & Blogs

The Fast Lane to Evidence? What the New EMA Report Means for Trial Emulation

The Fast Lane to Evidence? What the New EMA Report Means for Trial Emulation

The Fast Lane to Evidence? What the New EMA Report Means for Trial Emulation

The European Medicines Agency (EMA) just released its third annual report on real-world evidence (RWE) in regulatory decision-making and...

Jul 73 min read

The Trouble with Comparators: Fixing External Control Arms with Trial Emulation

The Trouble with Comparators: Fixing External Control Arms with Trial Emulation

The Trouble with Comparators: Fixing External Control Arms with Trial Emulation

Real-world evidence is becoming central to regulatory and HTA decision-making in rare diseases and it is so for good reason. In many rare...

Jul 13 min read

When Real-World Evidence Gets Real: Lessons from the Frontlines of Target Trial Emulation

When Real-World Evidence Gets Real: Lessons from the Frontlines of Target Trial Emulation

When Real-World Evidence Gets Real: Lessons from the Frontlines of Target Trial Emulation

It’s not every day that three leaders in epidemiology, health technology assessment, and regulatory science gather to discuss what might...

Jun 183 min read

What We Do
Resources
- Navigating Market Access
Case Studies and Blogs
About Us
- Our Differentiation
- Our Promise
Contact

Artboard 16.png

info@adigenshealth.com

© 2025 by Adigens Health. Designed and Maintained by Griffin Collective

bottom of page